Bioelectronics Corp (BIEL)

[doc063]

Duke, you have to understand that period was pre FDA approval. The product or company was being evaluated by many during that period. We are now in a different era post FDA approval. Expect revenues to increase as Actipatch becomes a household name, and investors fight for shares. Everything is timing. The timing now is on investors' side. Hence, this stock is grossly undervalued!